Genmab shares climb after head-and-neck cancer data as Iovance and Coherus stocks fall

Genmab's shares moved higher after the company released data from a head‑and‑neck cancer trial, which investors interpreted as a positive signal for the drug's potential.

In contrast, Iovance and Coherus saw their stock prices decline following the release of their own trial updates, which were less favorably received by the market.

The mixed outcomes underscore how recent oncology trial readouts continue to generate significant volatility across biotech equities.